Literature DB >> 2823752

Spectrum of inclusion body myositis.

S P Ringel1, C E Kenny, H E Neville, R Giorno, M R Carry.   

Abstract

The clinical, laboratory, and biopsy features are described for a large group of patients with inclusion body myositis (IBM) (15 men and four women; mean age, 63 years). A quantitative histopathologic analysis of muscle biopsy specimens revealed less fiber necrosis and endomysial and perivascular inflammation in IBM than in polymyositis (PM) and dermatomyositis, but a more frequent occurrence of dark-angular and hypertrophied fibers. Rimmed vacuoles were present in 3.4% of all fibers and 15- to 18-nm filaments were identified in the biopsy specimens of nine of 11 patients. A panel of monoclonal antibodies immunoreactive with lymphocytes and cells of monocyte/macrophage lineage suggested that the inflammatory reaction in IBM was similar to that in PM (but not dermatomyositis) and mediated by cellular immune responses. These studies confirm the clinical and histopathologic distinctions between IBM and chronic PM, and that differentiation between these disorders is often difficult.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823752     DOI: 10.1001/archneur.1987.00520230042011

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

1.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  Inflammatory and non-inflammatory inclusion body myositis. Characterization of the mononuclear cells and expression of the immunoreactive class I major histocompatibility complex product.

Authors:  D Figarella-Branger; J F Pellissier; N Bianco; B Devictor; M Toga
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

3.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Johannes C van Houwelingen; Peter A van Doorn; Sjoerd G van Duinen; Baziel G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne de Visser; Jan J G M Verschuuren; Axel R Wintzen
Journal:  J Neurol       Date:  2005-06-17       Impact factor: 4.849

Review 4.  P62/SQSTM1 at the interface of aging, autophagy, and disease.

Authors:  Alessandro Bitto; Chad A Lerner; Timothy Nacarelli; Elizabeth Crowe; Claudio Torres; Christian Sell
Journal:  Age (Dordr)       Date:  2014-02-21

5.  Inclusion body myositis with abundant ring fibers.

Authors:  M R Del Bigio; V Jay
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

6.  Inclusion body myositis: an underdiagnosed condition?

Authors:  N D Hopkinson; C Hunt; R J Powell; J Lowe
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

7.  Inclusion body myositis: clinical and histopathological features of 36 patients.

Authors:  S Beyenburg; S Zierz; F Jerusalem
Journal:  Clin Investig       Date:  1993-05

8.  Dysphagia in inclusion body myositis.

Authors:  A R Wintzen; G T Bots; H M de Bakker; J H Hulshof; G W Padberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-12       Impact factor: 10.154

9.  Inclusion body myositis: a case of bilateral extremity weakness.

Authors:  Luke Lam; Stephen Scheper; Natalia Zagorski; Mark Chung; Hiroji Noguchi; Kore K Liow
Journal:  Hawaii J Med Public Health       Date:  2013-12

Review 10.  Ongoing developments in sporadic inclusion body myositis.

Authors:  Pedro M Machado; Mhoriam Ahmed; Stefen Brady; Qiang Gang; Estelle Healy; Jasper M Morrow; Amanda C Wallace; Liz Dewar; Gita Ramdharry; Matthew Parton; Janice L Holton; Henry Houlden; Linda Greensmith; Michael G Hanna
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.